Home › Companies › Rigel Pharmaceuticals, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Rigel Pharmaceuticals, Inc.’s Form 8-K, filed 2026-05-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Rigel Pharmaceuticals, Inc. in the interactive database Compare manager voting policies
These tallies are Rigel Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-05-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Alison Hannah, M.D. | 9,202,113 | -- | 49,583 | 1,469,709 | 3,406,029 | Majority: yes |
| Elect Director: Walter Moos, Ph.D. | 10,436,673 | -- | 41,996 | 242,736 | 3,406,029 | Majority: yes |
| Elect Director: Raul Rodriguez | 10,486,503 | -- | 42,288 | 192,614 | 3,406,029 | Majority: yes |
| Approval of the Amended 2018 Equity Incentive Plan The Company's stockholders approved the Amended 2018 Equity Incentive Plan. | 6,497,964 | 3,813,701 | 409,740 | -- | 3,406,029 | Majority: yes |
| Approval of the 2000 Employee Stock Purchase Plan The Company's stockholders approved the Amended 2000 Employee Stock Purchase Plan. | 9,840,922 | 475,464 | 405,019 | -- | 3,406,029 | Majority: yes |
| Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. | 9,013,480 | 1,291,609 | 416,316 | -- | 3,406,029 | Majority: yes |
Source: Rigel Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-05-20 — read the filing on EDGAR.
Each item below shows how the 212 asset managers that disclosed a Rigel Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Rigel Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 9,013,480 for, 1,291,609 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 49.2% for, 7% against (56% of the company cast a for/against vote).
The 211 asset managers below cast 89% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,070,224 | 1 | 0 | 0 | For |
| American Century | 0 | 1,026,164 | 0 | 0 | Against |
| State Street | 984,478 | 1,100 | 0 | 0 | For |
| BlackRock | 909,568 | 7,693 | 0 | 0 | For |
| Fidelity | 468,813 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 453,123 | 626 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 406,057 | 0 | 0 | 0 | For |
| Charles Schwab | 347,292 | 0 | 0 | 0 | For |
| Nuveen | 337,449 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| LSV ASSET MANAGEMENT | 324,707 | 0 | 0 | 0 | For |
| Goldman Sachs | 286,829 | 0 | 0 | 0 | For |
| Janus Henderson | 275,556 | 0 | 0 | 0 | For |
| SEI | 185,364 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 175,557 | 0 | 0 | 0 | For |
| GLOBEFLEX CAPITAL L P | 174,308 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 160,000 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 135,284 | 0 | 0 | 0 | For |
| Dimensional | 124,164 | 0 | 0 | 0 | For |
| DE Shaw | 121,902 | 0 | 0 | 0 | For |
| Russell Investments | 118,221 | 0 | 0 | 0 | For |
| Northern Trust | 95,092 | 0 | 0 | 0 | For |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Renaissance | 76,776 | 0 | 0 | 0 | For |
Showing the 25 largest of 211 asset managers. See all 211 in the interactive database.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Alison Hannah, M.D.”): 9,202,113 for, 1,469,709 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 50.3% for, 8% withheld (58% of the company cast a for/withheld vote).
The 73 asset managers below cast 91% of the shares they voted on this item FOR (4,267,654 for, 436,903 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 919,098 | 586 | 0 | 0 | For |
| State Street | 652,162 | 180 | 0 | 0 | For |
| American Century | 500,742 | 0 | 0 | 0 | For |
| Fidelity | 414,473 | 0 | 0 | 0 | For |
| BlackRock | 361,647 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 173,646 | 0 | 0 | Against |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 135,284 | 0 | 0 | 0 | For |
| Dimensional | 87,624 | 0 | 0 | 0 | For |
| SEI | 0 | 85,784 | 0 | 0 | Against |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Goldman Sachs | 73,562 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 59,104 | 0 | 0 | 0 | For |
| ADVISORS' INNER CIRCLE FUND | 0 | 49,700 | 0 | 0 | Against |
| Russell Investments | 0 | 47,362 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 47,066 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 41,900 | 0 | 0 | 0 | For |
| Equitable | 28,522 | 9,604 | 0 | 0 | For |
| MFS | 37,099 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 0 | 35,000 | 0 | 0 | Against |
| JPMorgan | 26,272 | 0 | 0 | 0 | For |
| Lincoln Financial | 23,136 | 0 | 0 | 0 | For |
| ProShares | 19,595 | 0 | 0 | 0 | For |
| AQR | 19,309 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Raul Rodriguez”): 10,486,503 for, 192,614 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 57% for, 1% withheld (58% of the company cast a for/withheld vote).
The 73 asset managers below cast 99.7% of the shares they voted on this item FOR (4,694,954 for, 9,604 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 919,685 | 0 | 0 | 0 | For |
| State Street | 652,342 | 0 | 0 | 0 | For |
| American Century | 500,742 | 0 | 0 | 0 | For |
| Fidelity | 414,473 | 0 | 0 | 0 | For |
| BlackRock | 361,647 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| Charles Schwab | 173,646 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 135,284 | 0 | 0 | 0 | For |
| Dimensional | 87,624 | 0 | 0 | 0 | For |
| SEI | 85,784 | 0 | 0 | 0 | For |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Goldman Sachs | 73,562 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 59,104 | 0 | 0 | 0 | For |
| ADVISORS' INNER CIRCLE FUND | 49,700 | 0 | 0 | 0 | For |
| Russell Investments | 47,362 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 47,066 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 41,900 | 0 | 0 | 0 | For |
| Equitable | 28,522 | 9,604 | 0 | 0 | For |
| MFS | 37,099 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 35,000 | 0 | 0 | 0 | For |
| JPMorgan | 26,272 | 0 | 0 | 0 | For |
| Lincoln Financial | 23,136 | 0 | 0 | 0 | For |
| ProShares | 19,595 | 0 | 0 | 0 | For |
| AQR | 19,309 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Walter Moos, Ph.D.”): 10,436,673 for, 242,736 withheld, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 57% for, 1% withheld (58% of the company cast a for/withheld vote).
The 73 asset managers below cast 99.7% of the shares they voted on this item FOR (4,692,687 for, 10,951 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 918,435 | 1,251 | 0 | 0 | For |
| State Street | 651,421 | 0 | 921 | 0 | For |
| American Century | 500,742 | 0 | 0 | 0 | For |
| Fidelity | 414,473 | 0 | 0 | 0 | For |
| BlackRock | 361,647 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| Charles Schwab | 173,646 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 135,284 | 0 | 0 | 0 | For |
| Dimensional | 87,624 | 0 | 0 | 0 | For |
| SEI | 85,784 | 0 | 0 | 0 | For |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Goldman Sachs | 73,562 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 59,104 | 0 | 0 | 0 | For |
| ADVISORS' INNER CIRCLE FUND | 49,700 | 0 | 0 | 0 | For |
| Russell Investments | 47,362 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 47,066 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 41,900 | 0 | 0 | 0 | For |
| Equitable | 28,522 | 9,604 | 0 | 0 | For |
| MFS | 37,099 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 35,000 | 0 | 0 | 0 | For |
| JPMorgan | 26,272 | 0 | 0 | 0 | For |
| Lincoln Financial | 23,136 | 0 | 0 | 0 | For |
| ProShares | 19,595 | 0 | 0 | 0 | For |
| AQR | 19,309 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 5 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Approval of the 2000 Employee Stock Purchase Plan The Company's stockholders approved the Amended 2000 Employee Stock Purchase Plan.”): 9,840,922 for, 475,464 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 53.7% for, 3% against (56% of the company cast a for/against vote).
The 73 asset managers below cast 99.2% of the shares they voted on this item FOR (4,671,614 for, 37,088 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 918,433 | 1,252 | 0 | 0 | For |
| State Street | 651,447 | 895 | 0 | 0 | For |
| American Century | 500,742 | 0 | 0 | 0 | For |
| Fidelity | 414,473 | 0 | 0 | 0 | For |
| BlackRock | 361,647 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| Charles Schwab | 173,646 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 135,284 | 0 | 0 | 0 | For |
| Dimensional | 87,624 | 0 | 0 | 0 | For |
| SEI | 85,784 | 0 | 0 | 0 | For |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Goldman Sachs | 73,562 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 59,104 | 0 | 0 | 0 | For |
| ADVISORS' INNER CIRCLE FUND | 49,700 | 0 | 0 | 0 | For |
| Russell Investments | 47,362 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 47,066 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 41,900 | 0 | 0 | 0 | For |
| Equitable | 38,126 | 0 | 0 | 0 | For |
| MFS | 37,099 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 35,000 | 0 | 0 | 0 | For |
| JPMorgan | 26,272 | 0 | 0 | 0 | For |
| Lincoln Financial | 23,136 | 0 | 0 | 0 | For |
| ProShares | 19,595 | 0 | 0 | 0 | For |
| AQR | 19,309 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 5 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Approval of the Amended 2018 Equity Incentive Plan The Company's stockholders approved the Amended 2018 Equity Incentive Plan.”): 6,497,964 for, 3,813,701 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 35% for, 21% against (56% of the company cast a for/against vote).
The 71 asset managers below cast 71% of the shares they voted on this item FOR (3,343,510 for, 1,339,248 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 894,528 | 25,158 | 1 | 0 | For |
| State Street | 650,674 | 1,668 | 0 | 0 | For |
| American Century | 0 | 500,742 | 0 | 0 | Against |
| Fidelity | 343,785 | 70,688 | 0 | 0 | For |
| BlackRock | 361,647 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| Charles Schwab | 173,646 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 160,000 | 0 | 0 | Against |
| Janus Detroit Street Trust | 0 | 135,284 | 0 | 0 | Against |
| Dimensional | 87,624 | 0 | 0 | 0 | For |
| SEI | 85,784 | 0 | 0 | 0 | For |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 73,562 | 0 | 0 | Against |
| Pacer Funds Trust | 0 | 59,104 | 0 | 0 | Against |
| ADVISORS' INNER CIRCLE FUND | 49,700 | 0 | 0 | 0 | For |
| Russell Investments | 47,362 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 47,066 | 0 | 0 | Against |
| AMERICAN BEACON FUNDS | 0 | 41,900 | 0 | 0 | Against |
| Equitable | 28,522 | 9,604 | 0 | 0 | For |
| MFS | 37,099 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 35,000 | 0 | 0 | 0 | For |
| JPMorgan | 26,272 | 0 | 0 | 0 | For |
| Lincoln Financial | 12,106 | 11,030 | 0 | 0 | For |
| ProShares | 0 | 19,595 | 0 | 0 | Against |
| AQR | 0 | 19,309 | 0 | 0 | Against |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
91% fund support · no official result
The 71 asset managers below cast 91% of the shares they voted on this item FOR (4,265,464 for, 417,293 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 919,098 | 586 | 0 | 0 | For |
| State Street | 652,316 | 26 | 0 | 0 | For |
| American Century | 500,742 | 0 | 0 | 0 | For |
| Fidelity | 414,473 | 0 | 0 | 0 | For |
| BlackRock | 361,647 | 0 | 0 | 0 | For |
| TIAA | 331,121 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 173,646 | 0 | 0 | Against |
| Delaware/Macquarie | 160,000 | 0 | 0 | 0 | For |
| Janus Detroit Street Trust | 135,284 | 0 | 0 | 0 | For |
| Dimensional | 87,624 | 0 | 0 | 0 | For |
| SEI | 0 | 85,784 | 0 | 0 | Against |
| EA Series Trust | 82,368 | 0 | 0 | 0 | For |
| Goldman Sachs | 73,562 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 59,104 | 0 | 0 | 0 | For |
| ADVISORS' INNER CIRCLE FUND | 0 | 49,700 | 0 | 0 | Against |
| Russell Investments | 0 | 47,362 | 0 | 0 | Against |
| Principal Exchange-Traded Funds | 47,066 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 41,900 | 0 | 0 | 0 | For |
| Equitable | 38,126 | 0 | 0 | 0 | For |
| MFS | 37,099 | 0 | 0 | 0 | For |
| OPTIMUM FUND TRUST | 0 | 35,000 | 0 | 0 | Against |
| JPMorgan | 26,272 | 0 | 0 | 0 | For |
| Lincoln Financial | 23,136 | 0 | 0 | 0 | For |
| ProShares | 19,595 | 0 | 0 | 0 | For |
| AQR | 19,309 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. See all 71 in the interactive database.
95% Majority: yes · of votes cast
Rigel Pharmaceuticals, Inc.’s own tally for this item (“Approval of the 2000 Employee Stock Purchase Plan The Company's stockholders approved the Amended 2000 Employee Stock Purchase Plan.”): 9,840,922 for, 475,464 against, per its Form 8-K filed 2026-05-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 18,310,934 outstanding shares: 53.7% for, 3% against (56% of the company cast a for/against vote).
The 2 asset managers below cast 21% of the shares they voted on this item FOR (4,483 for, 17,317 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| CLEARWATER INVESTMENT TRUST | 0 | 17,317 | 0 | 0 | Against |
| FORUM FUNDS II | 4,483 | 0 | 0 | 0 | For |
100% fund support · no official result
The 2 asset managers below cast 100% of the shares they voted on this item FOR (21,800 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| CLEARWATER INVESTMENT TRUST | 17,317 | 0 | 0 | 0 | For |
| FORUM FUNDS II | 4,483 | 0 | 0 | 0 | For |
Ranked by the number of Rigel Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 18,310,934 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 5.84% |
| 2 | American Century | 5.60% |
| 3 | State Street | 5.38% |
| 4 | BlackRock | 5.01% |
| 5 | Fidelity | 2.56% |
| 6 | ACADIAN ASSET MANAGEMENT LLC | 2.48% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 2.22% |
| 8 | Charles Schwab | 1.90% |
| 9 | Nuveen | 1.84% |
| 10 | TIAA | 1.81% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 9.66% | 13F |
| State Street | 6.12% | 13F |
| Vanguard Group | 5.67% | 13F |
| D.E. Shaw | 2.43% | 13F |
| Geode Capital | 2.41% | 13F |
| Goldman Sachs | 2.40% | 13F |
| Two Sigma | 2.22% | 13F |
| Dimensional Fund Advisors | 2.07% | 13F |
| Renaissance Technologies | 1.85% | 13F |
| Millennium Management | 1.44% | 13F |
Percentages above are of 18,310,934 shares outstanding, as reported by Rigel Pharmaceuticals, Inc. on its Form 10-K dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Rigel Pharmaceuticals, Inc.’s 10-K dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Rigel Pharmaceuticals, Inc.'s shareholder meeting held 2026-05-14, in the 2025-2026 proxy season, 212 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,601 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Rigel Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-05-20.
Rigel Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).